Distinguished in ALK-Positive Non-Small Cell Lung Cancer

Dr. Nadeem Ikhlaque

Columbus Regional Health Physicians LLC
Columbus, IN
Distinguished
in ALK-Positive Non-Small Cell Lung Cancer
Specialties:Hematology Oncology | Oncology | Pain Medicine
Accepting New Patients
Offers Telehealth
OverviewInsuranceLocationsClinical Research

Overview

Nadeem Ikhlaque is a Hematologist Oncology specialist and an Oncologist in Columbus, Indiana. Dr. Ikhlaque and is rated as a Distinguished provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, Bone Marrow Aspiration, and Endoscopy. Dr. Ikhlaque is currently accepting new patients.

His clinical research consists of participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Pain Medicine
Licenses
Internal Medicine in WV
Hospital Affiliations
Columbus Regional Hospital
Languages Spoken
English
Hindi
Urdu
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  CareSource

Locations

COLUMBUS REGIONAL HEALTH PHYSICIANS LLC
2400 17th St, Columbus, IN 47201
812-373-3025

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Other, Procedure, Biological
Study Drug: Nivolumab
Study Phase: Phase 3
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Enrollment Status: Active_not_recruiting
Publish Date: February 25, 2025
Intervention Type: Drug, Procedure, Biological
Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Etoposide, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Rituximab, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer
An Adaptive Phase III, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (Bintrafusp Alfa) Versus Pembrolizumab as a First-line Treatment in Patients With PD-L1 Expressing Advanced Non-small Cell Lung Cancer
Enrollment Status: Completed
Publish Date: August 13, 2024
Intervention Type: Drug
Study Drugs: M7824, Pembrolizumab
Study Phase: Phase 3
An Observational Study Assessing the Clinical Effectiveness of VeriStrat and Validating Immunotherapy Tests in Subjects With Non-Small Cell Lung Cancer
An Observational Study Assessing the Clinical Effectiveness of VeriStrat and Validating Immunotherapy Tests in Subjects With Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 07, 2024
A Phase 2b Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults With Newly-Diagnosed Acute Myeloid Leukemia (AML), Not Eligible for Standard Induction Therapy
A Phase 2b Open-Label, Single Arm, Multi-Center Study to Assess the Efficacy and Safety of BST-236 as a Single Agent in Adults With Newly-Diagnosed Acute Myeloid Leukemia (AML), Not Eligible for Standard Induction Therapy
Enrollment Status: Completed
Publish Date: July 27, 2023
Intervention Type: Drug
Study Drug: Cytarabine
Study Phase: Phase 2
View 5 Less Clinical Trials
Similar Doctors
Nasser H. Hanna
Expertise in
17
conditions
Dr. Nasser H. Hanna
Hematology Oncology | Hematology | Oncology
Expertise in
17
conditions
Dr. Nasser H. Hanna
Hematology Oncology | Hematology | Oncology

University Medical Diagnostic Associates Inc

550 N University Blvd, 
Indianapolis, IN 
 (41.4 mi)
217-274-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nasser Hanna is a Hematologist Oncology specialist and a Hematologist in Indianapolis, Indiana. Dr. Hanna and is rated as an Elite provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Testicular Cancer, Orchiectomy, and Bone Marrow Transplant. Dr. Hanna is currently accepting new patients.

Expertise in
12
conditions
Dr. Shadia I. Jalal
Hematology Oncology | Hematology | Oncology
Expertise in
12
conditions
Dr. Shadia I. Jalal
Hematology Oncology | Hematology | Oncology

University Medical Diagnostic Associates Inc

535 Barnhill Dr, 
Indianapolis, IN 
 (41.4 mi)
317-274-8660
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Shadia Jalal is a Hematologist Oncology specialist and a Hematologist in Indianapolis, Indiana. Dr. Jalal and is rated as a Distinguished provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. Her top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), and Pleuropulmonary Blastoma. Dr. Jalal is currently accepting new patients.

Expertise in
124
conditions
Dr. Sumeet Bhatia
Oncology | Hematology | Hematology Oncology
Expertise in
124
conditions
Dr. Sumeet Bhatia
Oncology | Hematology | Hematology Oncology

Community Physicians Of Indiana Inc

7229 Clearvista Dr, Symptom Management Group, 
Indianapolis, IN 
 (47.7 mi)
317-621-4300
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sumeet Bhatia is an Oncologist and a Hematologist in Indianapolis, Indiana. Dr. Bhatia and is rated as a Distinguished provider by MediFind in the treatment of ALK-Positive Non-Small Cell Lung Cancer. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, Neuroendocrine Tumor, Bone Marrow Aspiration, and Gastrostomy. Dr. Bhatia is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile